Special Issue

Novel Insights into Tuberculosis Research and Drug Discovery

Message from the Guest Editor

Decades ago, it was anticipated that at this point in time, powerful antibiotics developed during the second half of the 20th century would have successfully eradicated tuberculosis. Unfortunately, virulent and deadly new strains have evolved, and the current situation is out of control. While this is a challenging objective, the current state of TB research is fascinating, and these are exciting times in which to contribute to the fight. Timely dissemination of research findings is unquestionably one of the most useful contributions that researchers can make to leverage their own discoveries. This Special Issue will focus on novel insights into tuberculosis research and drug discovery. Authors are welcome to contribute original research articles and reviews concerning not only new drugs and their mechanisms of action, but also new developments on existing and repurposing molecules. Explorations of prodrugs, formulation innovations, and alternative routes of drug delivery that may improve the performance of existing drugs are also welcome.

Guest Editor

Dr. Luís Constantino

Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

Deadline for manuscript submissions

closed (15 December 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/160153

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

